Liquid Biopsy Evaluation and Repository Development
common.study.values.description
“Liquid Biopsy Evaluation and Repository Development at Princess Margaret”
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods


common.study.methods.no-methods
participant.views.study.view.additional
participant.views.study.view.scientific-title
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
common.study.values.clinical-trial-id
NCT03702309
participant.views.study.view.id
eERxva